Imipramine Sensitizes Glioblastoma Cells to Temozolomide via PI3K/Akt Inhibition and Mitochondrial Apoptosis Induction
International Journal of Drug Research in Clinics · 01.01.2026 · 4 · e9101
DOI: 10.34172/ijdrc.9101 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Research in Clinics, online erschienen am 13.04.2026. Verfasst von Nazanin Bazazzadeh und 3 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Introduction
Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor, is characterized by a poor prognosis, with a median survival of only 12-18 months. This unfavorable outcome is largely attributed to severe resistance to temozolomide (TMZ), the standard chemotherapeutic agent used for treatment, which leads to treatment failure and tumor recurrence. Imipramine, a tricyclic antidepressant, has demonstrated potential as a modulator of signaling pathways. This study aimed to investigate the role of imipramine in increasing the sensitivity of U87MG glioblastoma cells to TMZ through the inhibition of the PI3K/Akt pathway.
Methods
In this experimental study, U87MG cells were treated with TMZ and imipramine, both as single agents and in combination. Cell survival and proliferation were assessed using the MTT assay. Gene expression levels of PI3K, Akt, Bax, Bcl-2, and Caspase-3 were measured via quantitative real-time polymerase chain reaction (qRT-PCR). Apoptosis rates were also measured using enzyme-linked immunosorbent assay (ELISA) and flow cytometry.
Results
Individually, TMZ and imipramine exerted inhibitory effects on cell proliferation. However, their combination significantly reduced the TMZ IC50 value from 78 to 35 µM. Combination treatment led to a significant downregulation of PI3K and Akt gene expression accompanied by upregulation of Bax and Caspase-3 and downregulation of Bcl-2 ( P
Zitieren
APA
Bazazzadeh, N., Molavand, M., Yousefi, B., & Shimia, M. (2026). Imipramine Sensitizes Glioblastoma Cells to Temozolomide via PI3K/Akt Inhibition and Mitochondrial Apoptosis Induction. International Journal of Drug Research in Clinics, 4, e9101. https://doi.org/10.34172/ijdrc.9101
Vancouver
Bazazzadeh N, Molavand M, Yousefi B, Shimia M. Imipramine Sensitizes Glioblastoma Cells to Temozolomide via PI3K/Akt Inhibition and Mitochondrial Apoptosis Induction. International Journal of Drug Research in Clinics. 2026;4:e9101. doi:10.34172/ijdrc.9101
BibTeX
@article{Bazazzadeh2026,
author = {Bazazzadeh, Nazanin and Molavand, Mehran and Yousefi, Bahman and Shimia, Mohammad},
title = {Imipramine Sensitizes Glioblastoma Cells to Temozolomide via PI3K/Akt Inhibition and Mitochondrial Apoptosis Induction},
journal = {International Journal of Drug Research in Clinics},
year = {2026},
volume = {4},
pages = {e9101},
doi = {10.34172/ijdrc.9101}
}
EUVIMED